Clinical Trial Detail

NCT ID NCT03125239
Title Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid Leukemia
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Jacqueline Garcia, MD
Indications

acute myeloid leukemia

Therapies

LY2874455 + Merestinib

Age Groups: adult senior

No variant requirements are available.